<DOC>
	<DOCNO>NCT01809301</DOCNO>
	<brief_summary>The objective study compare absorption niacin metabolite ( 1-methylnicotinamide , 1-MNA ) TRIA-662 ( 1-methylnicotinamide chloride ) relative production 1-MNA Niaspan . The 1-MNA information obtain study use adjust top dose plan TRIA-622 efficacy study .</brief_summary>
	<brief_title>Comparison TRIA-662 500 mg Niaspan 1000 mg Healthy Male Female Volunteers Under Fed Conditions</brief_title>
	<detailed_description />
	<mesh_term>Nicotinic Acids</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<criteria>Main Inclusion Criteria 1 . Healthy , nonsmoking ( least 6 month prior drug administration ) , male female volunteer , 3565 year age , inclusive . 2 . Body weight within 30 % ideal body weight . 3 . Healthy , accord medical history , ECG , vital sign , laboratory result physical examination determine Principal Investigator/SubInvestigator . 4 . Systolic blood pressure 100140 mmHg , inclusive , diastolic blood pressure 6090 mmHg , inclusive , heart rate 50100 bpm , inclusive , unless deem otherwise Principal Investigator/SubInvestigator . Main Exclusion Criteria 1 . Known history presence clinically significant hepatic ( e.g . active liver disease , hepatic necrosis , jaundice , hepatobiliary disease , hepatic dysfunction ) , renal/genitourinary ( e.g . renal impairment , renal dysfunction ) , gastrointestinal , cardiovascular ( e.g . angina , myocardial infarction ) , cerebrovascular , pulmonary , endocrine ( e.g . diabetes , hypophosphatemia , ) , immunological , musculoskeletal ( e.g . rhabdomyolysis , myopathy ) , neurological , psychiatric , dermatological hematological condition unless determine clinically significant Principal Investigator/SubInvestigator . 2 . Clinically significant history presence clinically significant gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , condition know interfere absorption , distribution , metabolism excretion drug experience within 7 day prior first drug administration , determine Principal Investigator/SubInvestigator . 3 . Known presence active bleeding . 4 . Known history presence : Alcohol abuse dependence within one year prior drug administration . Drug abuse dependence . Hypersensitivity idiosyncratic reaction niacin , excipients ( e.g . methyl cellulose , povidone , stearic acid ) , and/or related substance ( e.g . nicotinamide [ Vit . B3 ] ) . Hypertension require treatment Active peptic ulcer Hypo hyperthyroidism treat stable least 6 month Gout Food allergy and/or presence dietary restriction . Severe allergic reaction ( e.g . anaphylactic reaction , angioedema ) . 5 . Intolerance and/or difficulty blood sample venipuncture . 6 . Use prescription medication within 30 day prior drug administration ( except hormonal contraceptive ) . 7 . Use overthecounter medication vitamin ( include herbal and/or dietary supplement and/or tea ) within 14 day prior drug administration ( except spermicidal/barrier contraceptive product ) . 8 . Use statin ( e.g . lovastatin , simvastatin ) , bile acid sequestrants ( e.g . cholestyramine ) , aspirin , antihypertensive therapy , vasoactive drug ( e.g . nitrate ) , calcium channel blocker , adrenergic block agent , anticoagulant vitamin ( e.g . multivitamin ) within 30 day prior drug administration . 9 . Women pregnant , plan become pregnant study nursing .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Bioavailability</keyword>
</DOC>